<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03353493</url>
  </required_header>
  <id_info>
    <org_study_id>314 #2016-051-000001</org_study_id>
    <nct_id>NCT03353493</nct_id>
  </id_info>
  <brief_title>Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder</brief_title>
  <official_title>Neural, Molecular and Psychological Mechanisms and Predictors of Treatment Response to Mindfulness-based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VIA University College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate neural mechanisms and predictors of
      treatment outcome in Mindfulness-Based Cognitive Therapy (MBCT) for recurrent Major
      Depressive Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM AND HYPOTHESES

      The primary aim is to investigate treatment mechanisms of MBCT and markers of relapse risk.

      Controlled design:

      First, we aim to first investigate the effect of treatment on clinical outcomes in the
      controlled design post treatment and at 3 months follow up. Second, we will run mediation
      analyses of hypothesized mechanisms (increased mindfulness skills, decentering, interoceptive
      and decreased rumination, and change in neural connectivity in a priori networks), and
      finally check for moderating influences of vulnerability markers (childhood trauma, no.
      episodes of depression and residual symptoms).

      Prospective design:

      We aim to investigate predictors of relapse risk at 12 month follow treatment using i)
      baseline markers and ii) mechanism outcomes that change significantly due to treatment, and
      iii) check for moderating influences of vulnerability markers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised to Mindfulness-based cognitive therapy plus treatment as usual, or treatment as usual.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Participants are masked at baseline assessment to treatment allocation. Outcome assessors are masked to treatment allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neural connectivity</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Neural connectivity will be measured with functional magnetic resonance (fMRI). Selected a priory networks for seed-based analyses: Default mode Network and Salience Network</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mindfulness skills</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Five Factor Mindfulness Questionnaire (FFMQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in decentering</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Experiences Questionaire (EQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rumination</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Rumination Response Scale (RRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in emotional processing bias</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Facial Expression Recognition task (FERT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interoceptive awareness</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Multidimensional Assessment of Interoceptive Awareness (MAIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perceived stress</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse or recurrence of depression</measure>
    <time_frame>12 months follow up</time_frame>
    <description>Structured clinical interview for DSM-IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depressive symptoms</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Quick Inventory for Depressive Symptomology (QIDS-SR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin gene expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>IL-1, IL-2, IL-4,IL-6, IL-8, IL-10, IL-12p70, IL-13,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin protein expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>IL-1, IL-2, IL-4,IL-6, IL-8, IL-10, IL-12p70, IL-13,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression of norepinephrine transporter</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Norepinephrine transporter (NET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression of glutamate receptor</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Glutamate receptor (GRM7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gene expression of TNF</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change in gene expression of tumor necrosis factor (previous nomenclature TNF-alfa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in protein expression of tumor necrosis factor</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Tumor necrosis factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cRP expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>c reactive protein expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NF-kB gene expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Nuclear factor kappa-light-chain-enhancer of activated B cells gene expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NF-kB protein expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Nuclear factor kappa-light-chain-enhancer of activated B cells protein expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in INFG gene expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Interferon gamma gene expresison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interferon gamma protein expression</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Interferon gamma protein expresison</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial DNA Copy Number</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Copy number is assessed using quantitative real-time-PCR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>fMRI BOLD secondary and whole brain analyses</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>fMRI BOLD whole brain analyses (data-driven) and secondary subcortical seed-based analyses: As seeds we preselect hippocampus, the amygdala and striatum</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Gene expression with focus on genes involved in mitochondrial function, the respiratory chain.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>HG-U133 Plus 2.0 GeneChip (Affymetrix)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Major Depressive Disorder, Recurrent</condition>
  <arm_group>
    <arm_group_label>MBCT + TAU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MBCT</intervention_name>
    <description>Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams &amp; Teasdale (2013).</description>
    <arm_group_label>MBCT + TAU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TAU</intervention_name>
    <description>Treatment as usual (TAU)</description>
    <arm_group_label>MBCT + TAU</arm_group_label>
    <arm_group_label>TAU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age above 18 years

          2. Meeting DSM-IV criteria for a history of recurrent Major Depressive Disorder (MDD)
             with or without a current episode of depression

          3. Recurrent MDD evaluated a being the primary disorder.

          4. Danish literacy

        Exclusion Criteria:

          1. A history of schizophrenia, schizoaffective disorder, bipolar disorder, current severe
             substance abuse, organic mental disorder, current/past psychosis, pervasive
             developmental delay, persistent antisocial behaviour, persistent self-injury requiring
             clinical management/therapy

          2. Formal concurrent psychotherapy

          3. Previous Mindfulness-Based Cognitive Therapy/Mindfulness-Based Stress Reduction

          4. Anti-psychotic medication and benzodiazepines

          5. Standard exclusion criteria for undergoing magnetic resonance imaging (MRI) procedures
             for research purposes, i.e., claustrophobia, pregnancy, cardiac pacemaker, prosthetic
             heart valve, neurostimulator, implanted pumps, cochlear implants, non-MR-compatible
             implants or devices.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Maj van der Velden, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Medicine, Aarhus University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://interactingminds.au.dk/projects/mindfulness-and-the-prevention-of-depression/</url>
    <description>Study website</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Anne Maj van der Velden</investigator_full_name>
    <investigator_title>PhD fellow</investigator_title>
  </responsible_party>
  <keyword>Mindfulness-Based Cognitive Therapy</keyword>
  <keyword>Neural, psychological and molecular mechanisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

